Taysha Gene Therapies (TSHA) Other Working Capital Changes (2023 - 2025)

Taysha Gene Therapies (TSHA) has 3 years of Other Working Capital Changes data on file, last reported at -$5.5 million in Q4 2025.

• For the quarter ending Q4 2025, Other Working Capital Changes fell 171.27% year-over-year to -$5.5 million; the trailing twelve-month figure through Dec 2025 stood at -$9.8 million (down 17.28% YoY), and the FY2025 full-year result was -$9.8 million, down 17.28% from the prior year.
• Other Working Capital Changes retreated to -$5.5 million in Q4 2025, from -$2.0 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $2.1 million in Q4 2025 to a low of -$3.5 million in Q3 2023.
• A 5-year average of -$339882.4 and a median of -$271000.0 in 2022 frame the typical range for Other Working Capital Changes.
• Across the five-year window, Other Working Capital Changes jumped 62.33% in 2024 and plunged 171.27% in 2025, its largest moves.
• Tracing TSHA's Other Working Capital Changes over 3 years: stood at -$3.6 million in 2023, then soared by 43.9% to -$2.0 million in 2024, then sank by 171.27% to -$5.5 million in 2025.
• Business Quant data shows TSHA's Other Working Capital Changes at -$5.5 million in Q4 2025, -$2.0 million in Q2 2025, and -$2.3 million in Q1 2025.